12
NEWS
Making more friends
A look at companies in the diabetes sector which are
working with each other to improve their offerings to
people with diabetes.
Glooko
Glooko, Inc has announced a new
global partnership with Hedia,
integrating its technology into
Glooko's diabetes management
platforms for healthcare providers
and people with diabetes. The
collaboration will bring together
connected care, remote patient
monitoring and digital therapeutic
technologies to enhance access
for people with Type 1 and Type
2 diabetes requiring insulin
dosing advice.
With the Glooko platforms,
patients currently have the ability
to share their diabetes data with
their healthcare providers (HCPs),
including blood glucose readings,
insulin doses, food and carbs,
exercise activity, blood pressure and
weight. With the integration of the
Hedia Diabetes Assistant, people with
diabetes will be able to receive bolus
insulin dosing advice, which will
provide personalized care and reduce
the burden of manually calculating
required insulin doses.
In addition, when used in
conjunction with connected insulin
pens, the integrated solution
facilitates a high level of visibility for
HCPs who are managing patients
on multiple daily injection (MDI)
therapy. This integration enhances
the capabilities of Glooko's remote
patient monitoring (RPM) and
supports virtual consultations for
MDI patients.
CamAPS FX is now compatible
with Glooko. Once the new CamAPS
FX app update has been released
(version 1.4(170), which will be
available from mid-April) existing
users will receive an in-app message
prompting them to update the app
which will upgrade their existing
Diasend accounts to communicate
their data to Glooko.
www.glooko.com
Innovation Zed
Innovation Zed, a company based
in Ireland, specialises in the
development of innovative medical
devices. It has partnered with
GluCare.Health, a leading metabolic
disease management platform,
to provide connected insulin
pen technology.
Innovation Zed's medical device
technologies include a range of
smart add-on devices that can
automatically log injection data
and store vital injection history for
Multiple Daily Injection (MDI) users.
Marketed under the InsulCheck
brand, these products capture
valuable injection data such as the
timestamp of injection events, insulin
dose dialled and temperature.
By integrating these technologies,
GluCare.Health is better positioned
to support its insulin-dependent
patients with real-time feedback
of insulin doses and timings. This
enables the company to build a more
comprehensive picture of patients'
health status and needs.
www.innovationzed.com
Medtronic
Medtronic has begun working with
computer chip maker Nvidia on a
platform for artificial intelligence
applications to run on its
medical devices.
The companies hope to create a
medical device marketplace for AI
apps, using Medtronic devices and
Nvidia's chips, where physicians and
developers would be able to create
their own algorithms to use on the
machines. New algorithms generally
require a rigorous review by the U.S.
Food and Drug Administration, but
Medtronic said this development
may help some developers win
that approval.
www.medtronic.com
InsulCheck DOSE.